Search

Search Results

1. Local ocular safety of the subconjunctival injection of cetuximab in rabbits

   Background

   To evaluate the safety of different doses of subconjunctival cetuximab in rabbits.

   Methods

   After general anesthesia rabbits received a...

   Hossein Aghaei, Ahmad Kheirkhah, ... Samira Chaibakhsh in BMC Ophthalmology

   Article Open access 13 April 2023
   

2. Development of ¹⁷⁷Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate

   Purpose

   Epidermal growth factor receptors (EGFRs) are overexpressed in a wide range of tumors and are attractive candidates to target in targeted...

   Seyed Mohammad Hosseini, Javad Mohammadnejad, ... Ali Hossein Rezayan in Journal of Cancer Research and Clinical Oncology

   Article 08 April 2023
   

3. Cetuximab/imatinib/sunitinib

   in Reactions Weekly

   Article 12 November 2022

4. Cetuximab

   in Reactions Weekly

   Article 19 February 2022

5. Erasing Giant Folds: Ménétrier's Disease Treated with Cetuximab

   Hannah Ramrakhiani, George Triadafilopoulos in Digestive Diseases and Sciences

   Article 20 September 2022
   

6. Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients

   Purpose

   Cetuximab inhibits epidermal growth factor receptor (EGFR) signaling in cancer and skin cells, thereby inducing anti-cancer effects and skin...

   Kaito Shibata, Takafumi Naito, ... Junichi Kawakami in Cancer Chemotherapy and Pharmacology

   Article 19 January 2021
   

7. Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer

   Epidermal growth factor receptor (EGFR) is commonly overexpressed in many head and neck squamous cell carcinomas (HNSCC). With the success of EGFR...

   Praveena Tathineni, Nikhil Joshi, Michael J. Jelinek in Current Treatment Options in Oncology

   Article 17 April 2023

8. Synthesis and preclinical evaluation of [¹¹C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor

   Background

   Mutations in the epidermal growth factor receptor (EGFR) kinase domain are common in non-small cell lung cancer. Conventional tyrosine...

   Antonia A. Högnäsbacka, Alex J. Poot, ... Albert D. Windhorst in EJNMMI Research

   Article Open access 16 February 2024
   

9. Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study

   Introduction

   Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT)...

   Tao Jiang, Hao Chen, ... **aoyan Lin in Advances in Therapy

   Article 07 May 2020
   

10. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment

    Background Overcoming resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) in patients with KRAS wildtype (WT)...

    Jean-Pierre Delord, Guillem Argilés, ... Lillian L. Siu in Investigational New Drugs

    Article 14 May 2020
    

11. Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant

    Background

    Oncogenic mutations in BRAF genes are found in approximately 5–10% of colorectal cancers. The majority of BRAF mutations are located...

    Chikako Nakai, Sachiyo Mimaki, ... Katsuya Tsuchihara in International Journal of Clinical Oncology

    Article Open access 01 March 2023
    

12. Multiple drugs

    in Reactions Weekly

    Article 23 March 2024

13. Pharmacoeconomic Appraisal of Treating Head and Neck Cancer with Various Chemotherapy and Chemoirradiation Regimens Using Branded and Jan-aushadhi Drugs in India

    According to recent studies, head and neck cancers (HNC) make up a substantial proportion of all cancers in India and are proportionately high in the...

    Abhishek Krishna, Mamatha Jayachandran, ... Manjeshwar Shrinath Baliga in Indian Journal of Otolaryngology and Head & Neck Surgery

    Article 08 April 2023

14. The potential of monoclonal antibodies for colorectal cancer therapy

    Conventional chemotherapy has significant limitations for colorectal cancer (CRC) treatment, especially those who have developed metastatic...

    Fatemeh Heidari, Soheil Madadi, ... Meysam Soleimani in Medical Oncology

    Article 21 August 2023
    

15. Efficacy and safety of triplet chemotherapy plus anti-EGFR agents in metastatic colorectal cancer: a systematic review and meta-analysis

    Background

    To date, the optimal treatment for potentially resectable metastatic colorectal cancer (mCRC) patients has yet to be determined....

    Qian Wu, Huan Wang, ... Wenbin Gao in World Journal of Surgical Oncology

    Article Open access 15 August 2022
    

16. Antineoplastics

    in Reactions Weekly

    Article 18 June 2022

17. Multiple drugs

    in Reactions Weekly

    Article 02 April 2022

18. Blood–Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade

    Purpose of Review

    To review relevant advances in the past half-decade in the treatment of primary brain tumors via modification of blood–brain barrier...

    Piiamaria S. Virtanen, Kyle J. Ortiz, ... Angela M. Richardson in Current Oncology Reports

    Article 08 February 2024
    

19. Multiple drugs

    in Reactions Weekly

    Article 08 January 2022

20. Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

    Background

    Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial...

    Yen-Cheng Chen, Ching-Wen Huang, ... Jaw-Yuan Wang in World Journal of Surgical Oncology

    Article Open access 01 December 2023